Rafael Holdings Completes Cyclo Therapeutics Merger

Introduction

RAFAEL Holdings Inc (NYSE: RFL) is a clinical-stage biotechnology company focused on developing treatments for rare and difficult-to-treat diseases. As of June 19, 2025, its shares closed at US$1.57, reflecting a decrease of 19.07% from the previous session, on a trading volume of 728,279 shares. The company’s 52-week trading range is US$1.27 to US$3.19.

Corporate Structure

Rafael Holdings operates through a wholly-owned and controlled portfolio of subsidiaries and equity interests:

• Cyclo Therapeutics, LLC (100% interest), focused on Trappsol® Cyclo™, currently in Phase 3 trials for Niemann-Pick Disease Type C1 (NPC1).
• LipoMedix Pharmaceuticals Ltd. (majority interest), a clinical-stage pharmaceutical company.
• Barer Institute Inc., a preclinical cancer metabolism research operation.
• Cornerstone Pharmaceuticals, Inc. (majority interest), developing cancer metabolism therapeutics.
• Rafael Medical Devices, LLC (majority interest), developing orthopedic instruments for minimally invasive surgeries.
• Day Three Labs, Inc. (majority interest), enabling third-party manufacturers to develop cannabis products.

The board of directors includes Howard S. Jonas (Chairman), Stephen Greenberg, and Boris C. Pasche, MD, PhD.

Developments

On March 26, 2025, Rafael Holdings completed its merger with Cyclo Therapeutics following approvals from shareholders of both companies. Under the merger terms, Rafael issued Class B common stock representing approximately 22% of the combined company and additional warrants related to Cyclo Therapeutics’ outstanding warrants. Since then, Rafael has:

• Announced a US$25 million rights offering, distributing one non-transferable subscription right per share of Class A or Class B common stock held as of May 9, 2025. Each right entitles holders to purchase 0.603 shares of Class B common stock at US$1.28 per share.
• Updated subscription rights on May 5 and May 20, 2025, clarifying eligibility and procedures for exercising rights ahead of the offering’s expiration on May 29, 2025.
• Filed Form 8-K disclosures on June 11 and June 18, 2025, under Items 2.02, 7.01, 8.01, and 9.01, addressing relevant corporate events and regulatory updates.

Financial and Strategic Analysis

As of its June 11, 2025 10-Q:

• Market capitalization: US$76.72 million
• Trailing twelve-month revenue: US$0.732 million
• Net loss (TTM): US$22.89 million; diluted EPS (TTM): –US$0.92
• Total cash (MRQ): US$37.94 million; debt/equity (MRQ): 0.82%
• Price/sales (TTM): 70.15; price/book (MRQ): 0.93

Rafael’s strategy focuses on advancing Trappsol® Cyclo™ through TransportNPC™, a multi-center, randomized, double-blind, placebo-controlled study in pediatric and adult NPC1 patients, with an interim analysis expected in mid-2025. The merger with Cyclo aims to enhance clinical progress and leverage combined resources across Rafael's oncology and medical-device subsidiaries.

Market Position and Industry Context

Rafael Holdings operates within the orphan-disease and oncology therapeutics space, positioning itself in the small-cap biotech sector. Its focus on NPC1 aligns with orphan-drug incentives in the U.S. and Europe. The company’s diversified portfolio encompasses early-stage oncology research, medical devices, and cannabis technology, which may provide value across multiple avenues. However, the high price/sales multiples and reported losses reflect the developmental stage of its operations and dependence on successful clinical trials.

TL;DR

On March 26, 2025, Rafael Holdings finalized its merger with Cyclo Therapeutics, consolidating Trappsol® Cyclo™ assets under NYSE: RFL. A US$25 million rights offering—priced at US$1.28 per share and set to expire on May 29, 2025—seeks to support ongoing trials. Clinical teams are anticipating a 48-week interim analysis of the TransportNPC™ Phase 3 trial in mid-2025, marking a significant milestone for the treatment of Niemann-Pick Disease Type C1. As of June 19, 2025, the share price decreased 19.07% to US$1.57, reflecting market conditions associated with development-stage biotech investments.